Clinical trial
Darbepoetin Alfa in Patients With "Poor Prognosis" Germ Cell Tumor Treated With…
NCT00204633 · University Hospital Tuebingen, Other · Completed
Key facts
| NCT number | NCT00204633 |
|---|---|
| Title | Darbepoetin Alfa in Patients With "Poor Prognosis" Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP) |
| Official title | Randomized Phase II-Trial to Determine the Impact of Darbepoetin Alfa on the Frequency of RBC Transfusions in Patients With Metastatic "Poor Prognosis" Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP Regimen) |
| Lead sponsor | University Hospital Tuebingen, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Dysgerminoma |
| Intervention type | Drug |
| Interventions | Darbepoetin alfa |
| Enrollment | 108 |
| Start date | Jul 1, 2003 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Sep 20, 2005 |
| Last update posted | Feb 16, 2009 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: